Sanofi, Lonza to create JV (50:50) to produce monoclonal antibodies

Sanofi and Lonza announced today before markets opened that they have entered into a strategic partnership to build a Joint Venture whose main asset will be a facility for monoclonal antibody development and production in Lonza’s Visp site, Switzerland. The JV will have an initial capital of CHF 290m, to which the two companies will contribute equally. Construction will begin as early as 2017, and the plant is expected to be operational by 2020. Lonza has previously built and licensed three similar facilities in the US and Singapore. Through this agreement, Sanofi has secured the supply of materials to manufacture biologic therapeutic products in the future, while Lonza will be free to market unused Sanofi production capacity.
(Source Lonza)